The first hemophilia B patient in Germany received gene therapy Hemgenix, covered by public healthcare with efficacy-tied reimbursement.

Columnist Jennifer Lynne reflects on a women's retreat, where shared stories revealed gaps in medical care and the need for community.

The Haemophilia Society said the UK Government's failure to listen to victims was 'shamefully exposed' by the Infected Blood ...

Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

In this prospective cohort study, a single intravenous dose of scAAV2/8-LP1-hFIXco gene therapy in men with severe hemophilia B led to sustained factor IX expression and significantly reduced bleeding ...

CSL will consolidate its R&D teams around six sites located in biotech hubs as the company looks to boost external ...

A single infusion of adeno-associated virus (AAV)-mediated gene therapy led to sustained clinical benefit and no late-onset safety concerns in patients with severe hemophilia B, a longitudinal ...

Certain immune markers in the blood may help predict ITI response among hemophilia A patients given immune tolerance ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the most undervalued US stocks according to analysts. On June 24, ...

Pfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating patients with hemophilia A or B with inhibitors met its primary endpoint as ...